key: cord-0801141-qwqvjnev
authors: Rader, Theodore S.; Stevens, Michael P.; Bearman, Gonzalo
title: Syndromic Multiplex Polymerase Chain Reaction (mPCR) Testing and Antimicrobial Stewardship: Current Practice and Future Directions
date: 2021-02-26
journal: Curr Infect Dis Rep
DOI: 10.1007/s11908-021-00748-z
sha: 8a0bac1fccc8342133c4d04837ea2828215364b7
doc_id: 801141
cord_uid: qwqvjnev

PURPOSE OF REVIEW: Syndromic multiplex polymerase chain reaction (mPCR) panels offer the antimicrobial steward a rapid tool for optimizing and de-escalating antimicrobials. In this review, we analyze the role of syndromic mPCR in respiratory, gastrointestinal, and central nervous system infections within the context of antimicrobial stewardship efforts. RECENT FINDINGS: For all mPCR syndromic panels, multiple studies analyzed the pre-and-post implementation impact of mPCR on antimicrobial utilization. Prospective studies and trials of respiratory mPCR stewardship interventions, including diagnostic algorithms, educational efforts, co-testing with procalcitonin, and targeted provider feedback currently exist. For gastrointestinal and cerebrospinal fluid mPCR, fewer peer-reviewed reports exist for the use of mPCR in antimicrobial stewardship. These studies demonstrated an inconsistent trend towards decreasing antibiotic use with mPCR. This is further limited by a lack of statistical significance, the absence of controlled, prospective trials, and issues with data generalizability. SUMMARY: Antibiotic overuse may improve when mPCR is coupled with electronic medical record algorithm-based approaches and direct provider feedback by an antimicrobial stewardship professional. mPCR may prove a useful tool for antimicrobial stewardship but future studies are needed to define the best practice for its utilization.

Since the approval by the FDA of the first multiplex Polymerase Chain Reaction (mPCR) panel for the detection of respiratory pathogens, the BioFire Respiratory Pathogen Panel, the landscape of syndromic multiplex PCR panel testing continues to evolve [1, 2] . These tests, which subsequently expanded to include gastrointestinal (GI), bloodstream, and central nervous system (CNS) syndromic panels in addition to the respiratory panel, promise rapid turnaround times with high sensitivity and specificity when compared to more traditional methods such as culture [3] . Clinicians can gain rapid information regarding the nature of a patient's illness to guide clinical care, such as the timely initiation of targeted antimicrobials. Challenges remain in defining the best utilization of these syndromic panels in clinical care, and while many practice guidelines contain statements advising consideration of PCR-based diagnosis as part of the diagnostic workup, there are no recommendations provided on the best utilization of these panels [4, 5] .

Additionally, global concern about the rise of antimicrobial resistance driven by antibiotic overprescribing continues to increase. Syndromic mPCR panels offer rapid information useful to target or remove antimicrobials in the clinical context This article is part of the Topical Collection on Healthcare Associated Infections of a patient. The Society for Healthcare Epidemiology of America (SHEA) recently released a white paper outlining research needs for antimicrobial stewardship. Among the many suggested high-value targets for stewardship, mPCR has obvious benefits to drive practice changes in the prescription of antibiotics via diagnostic stewardship. This review provides an overview of the antimicrobial stewardship intervention landscape for respiratory, GI, and CNS panels. It will examine the types of studies conducted, the methods taken for stewardship, and the results of those efforts in improving the appropriate use of antibiotics.

The introduction of the BioFire FilmArray Respiratory Pathogen panel in 2011 marked a new era of rapid diagnostic testing for respiratory viral and bacterial pathogens. Since then, several other panels have been approved, including the Verigene, Luminex x-TAG series, eSensor Respiratory Virus Panel (RVP), and ePlex systems. This review is not meant to be a comprehensive review of the technical details of respiratory mPCR panels, and more comprehensive technical reviews are available elsewhere [1, 6] . In general, the sensitivities and specificities of the panels vary by which test is used and what virus is tested. The BioFire Respiratory Pathogen panel has nearly 99-100% specificity for the viruses included, but the sensitivity for certain viruses ranges from 57-100% depending on the study examined and the virus in question. In one example, Popwich et al. found that the FilmArray Respiratory Pathogen panel was 57% sensitive for adenovirus, whereas Rand et al. found sensitivity of 90% [7, 8] . For the eSensor RVP, the reported sensitivities range from 92 to 100% with specificity of 100% [1, 7] . For the x-TAG series, sensitivity and specificity are reported by panel types x-TAG RVP, x-TAG RVP Fast, and Nx-TAG. Nx-TAG is the current version of rapid syndromic mPCR available from Luminex, and reported sensitivity is 93-100% for most viruses with the exception of coronavirus HKU1 and OC43, with reported sensitivities of 67% each. Additionally calculated specificity is >97% for all included viral pathogens in this study [9] . Examining the underlying data, low sample numbers may limit interpretation of these results for the Nx-TAG, with only 3 positives in the sample set for coronavirus HKU1 and OC43. Generally, mPCR for respiratory pathogens should be considered sensitive and specific for identifying respiratory pathogens.

One advantage syndromic mPCR panels offer over more traditional methods is in the turnaround time of the panel. Depending on the collection method and timing for sample processing, the turnaround time can be as low as 1.5 h, but can be longer if samples are run in a batched fashion [10] [11] [12] [13] [14] [15] [16] [17] . This faster turnaround time translates into better antibiotic prescribing in some cases; in one example, a multiplex influenza/RSV assay changed the antimicrobials prescribed in 58% of patients in an emergency room setting, decreasing inappropriate antibiotic and antiviral prescriptions by 24.5% and 9%, respectively [12] . In the context of identifying influenza infections, multiple studies showed influenza virus-positive patients receive fewer antibiotics than influenza-negative patients [11] [12] [13] . More of these patients also receive oseltamivir or other antiviral medications, and mPCR reduces the time to delivery of antiviral medications [17] . The absence of influenza or the positive presence of another pathogen did not significantly change the rate of antibiotics prescribed, and there was no difference in the rates of antibiotics, 48.6% vs 49.3% in one study. Of the patients with a positive viral panel for influenza or other non-influenza viruses, 32% still received antibiotics [17] . In the ResPOC trial, one of the few randomized controlled trials pertaining to stewardship and mPCR panels, patients were randomized over two respiratory virus seasons to utilize the BioFire Respiratory Panel or an in-house PCR to determine the effect on antibiotic utilization. No significant differences were found in the number of patients who received antibiotics or the mean duration of antibiotics. Importantly, significantly fewer patients in the mPCR group than the control group received more than one dose of antibiotics [18] . Implementation of an mPCR respiratory panel alone appears not to have a replicable significant impact on antibiotic use or duration of antibiotics.

Adding an educational intervention to the stewardship process may reduce antimicrobial use. In a retrospective study by Keske et al., an educational intervention conducted during the implementation of a respiratory mPCR panel significantly increased the rate of discontinued antibiotics and overall decreased total antibiotic prescriptions [19] . In a randomized controlled trial by Branche et al., investigators educated providers on how to utilize an mPCR panel and procalcitonin (PCT) level algorithm for antibiotic de-escalation prior to the implementation of the study and were sent reminders of the algorithm on patient enrollment. While no difference was found in the duration of antibiotics overall, subsequent analysis found that algorithm adherent patients received significantly fewer days of antibiotics and fewer algorithm patients received antibiotics at discharge. The authors note that providers prescribed antibiotics for patients with high procalcitonin values more often than they withheld antibiotics for patients with low procalcitonin values [20] . In subsequent analysis, an admitting diagnosis of pneumonia was associated with overruling the algorithm in patients, with 7% of patients in the algorithm-adherent category carrying this diagnosis vs. 26% of patients in the nonadherent group [21] . Viewing these results, there may be ways to educate and promote adherence to directed therapy, such as encouraging more direct algorithm adherence, or providing education on viral pneumonias. Adding a directed intervention by an external reviewer can improve antimicrobial stewardship using mPCR. In a prospective study by Lowe et al., an antimicrobial stewardship program (ASP) provider reviewed the patient's chart and the results of an mPCR panel to determine if a patient would benefit from an ASP consult to provide recommendations in an audit-and-feedback model. They achieved successful reduction of 1.3 days of antibiotics in the prospective ASP audit cohort, and if their recommendations were accepted, 3.6 fewer days of antibiotics [22] . Similarly, Abbas et al. at Virginia Commonwealth University Health System reported success with an ASP provider intensive measure. An ASP member contacted inpatient provider teams about patients with positive results from a respiratory mPCR panel and made recommendations to de-escalate, change, or discontinue antibiotics. The primary teams followed the recommendations of the ASP provider 66% of the time overall; however, when the recommendation was discontinuation or de-escalation, providers accepted 19% of the time [23] . More recently, the Cleveland Clinic Foundation Health system undertook a large, multisite trial of an ASP provider recommendation for patients with a positive mPCR panel. Of their interventions, primary teams followed only 47% (n=26) of the 55 recommendations. This did not translate into a significantly reduced duration of antibiotic therapy, and intervention of an ASP provider did not influence the de-escalation of any one antibiotic [24••] . These provider intensive interventions require the time of a trained professional to review charts and make recommendations to the primary medicine team, but a large percentage of recommendations are not accepted, which may be a limitation of this method and may not represent an appropriate utilization of stewardship resources.

In a possible demonstration of a rationale to overcome a stewardship provider intensive method, Moradi et al. combined several methods to reduce antibiotic use without the intervention of a trained provider. Patients in a pre-post quasi-experimental study with a PCT ≤0.25 ng/ml, a mPCR panel positive for 1 virus, and at least 1 systemic antibiotic automatically triggered an alert in the Electronic Medical Record (EMR) to display when any provider opened the chart. This "Best Practices Alert" (BPA) displayed for the provider the PCT value, mPCR results, and the active antibiotics. The provider was given options to suppress the alert temporarily or permanently, and the interactions by providers with this alert were tracked. Patients in the intervention group who triggered the alert had their average days of antibiotics reduced significantly by 2.2 days (5.8 vs 8.0). In the intervention group, more antibiotics were discontinued within 24 h of initiation, there were fewer days of antibiotic therapy, and fewer antibiotic prescriptions on discharge [25••] . Within the different strategies to improve antibiotic discontinuation, it appears that utilization of an EMR base practice alert, possibly in conjunction with procalcitonin, can improve the use of respiratory mPCR panels for stewardship.

When compared to respiratory pathogen mPCR, fewer gastrointestinal (GI) mPCR stewardship investigations exist. Available panels include the BioFire FilmArray Gastrointestinal Panel, Luminex xTAG Gastrointestinal Pathogen Panel, and Verigene enteric pathogens panel. Like other mPCR panels, GI mPCR provides a faster turnaround time when compared to traditional methods such as stool culture and examination for ova and parasites [26, 27•, 28] . mPCR panels detect pathogens 10-36% more often than traditional methods depending on the panel used. Sensitivity for the BioFire FilmArray GI mPCR ranged from 94.5% for 7 of the 22 pathogens in the panel to 100% for 10 of 22 pathogens in one study. Specificity ranged from 93.4-100% depending on the target organism in the same study [29] . In the only direct comparison of the three enteric pathogen mPCR panels, the Verigene enteric pathogen mPCR panel reported sensitivity and specificity for Campylobacter of 83. 3% [30] .

In a large retrospective analysis, patients whose diagnostic workup included mPCR received fewer antibiotics (36.2% vs 40.9%). Patients with PCR testing were also less likely to undergo additional endoscopy or imaging. There were important differences between the two groups in this study. The mPCR group was larger, older and more likely to be inpatient, limiting the interpretation of the true effect size of the mPCR intervention [31] .

Similar to respiratory mPCR panels, using a stewardship intervention to educate clinicians on mPCR and appropriate antibiotic use appears to change prescribing habits. This approach helped Keske et al. reduce the inappropriate use of antibiotics from 42.9% to 25.8% in the post intervention period. This effect was maintained with a larger sample size in the post-intervention group while still allowing unrestricted access to the testing [32] . In the only prospective trial of GI mPCR, parallel cultures conducted in conjunction with the BioFire GI panel compared antimicrobial use in new inpatient and outpatients, both adults and children, to a historical control group. The mPCR panel replaced conventional culture as the orderable test immediately prior to the study period. As the turnaround time of test results decreased, there was a significant trend towards targeted antibiotics being prescribed, and proportionally fewer patients had initiation of antimicrobial therapy empirically. There also appeared to be an increasing use of the test results to target antimicrobial therapy to the organism detected, as over a period of months from the implementation of the test, the increasing utilization of narrowly directed therapy was apparent [27•] .

These studies suggest a role in the use of mPCR GI panels for stewardship of antimicrobials and resources, although diagnostic test stewardship is an important consideration. In a retrospective cohort of patients in a single hospital system, patients with an initial negative GI mPCR result were retested within 4 weeks of the initial negative result, and the vast majority remained negative, with no significant rate of conversion to positives [33] . In a subsequent follow up study from the same group, only 3.9% of tests for patients admitted >72 h were positive, ignoring viral shedding and suspected false positives [34] . Taken together, these results suggest that it is reasonable to test patients suspected to have infectious diarrhea with mPCR at least once; however, patients hospitalized for >72 h likely do not benefit from testing, and that repeat testing for patients with continued symptoms is unlikely to yield a different result.

Currently, the BioFire FilmArray Meningitis/Encephalitis (ME) panel is the only mPCR test approved by the U.S. Food and Drug Administration for cerebrospinal fluid analysis. It evaluates for 14 bacterial, viral, and fungal pathogens and can provide results within 1 h (https://www.biofiredx. com/products/the-filmarray-panels/filmarrayme/), which has been born out in clinical scenarios with several studies reporting a turnaround time of less than 2 h [35] [36] [37] . This provides inherent advantages over cultures, which can take days to result and can be insensitive while specific [38] . In addition, a recent systematic review and meta-analysis determined the overall sensitivity and specificity to be 90% (95% CI 86-93%) and 97% (95% CI 94-99%) [39] . Advantages in sensitivity, specificity, and turnaround time should allow for quick de-escalation of antimicrobials if results of the PCR are negative, something not noted in several retrospective preand-post implementation studies.

Dack et al. and Chang et al. both conducted retrospective observational studies of the effect of implementation of the BioFire Meningitis-Encephalitis Panel on antimicrobial usage. Both found negative mPCR panel patients had a median duration of 3 and 4 days of antimicrobial therapy, respectively, but did not prove a statistically significant decrease in antimicrobial use [36, 40] . The reasons given for possible continuation of antimicrobials include clinicians' concerns with mortality, or unfamiliarity with new technologies. In another pre-and-post implementation observational study, Radmard and colleagues learned that despite a rapid turn-around time of 1.5 h, the median time to narrowing or discontinuation of antimicrobial therapy was 26.5 h, with 25% of patients remaining on empiric therapy 24-48 h after negative panel results. Radmard et al. did not compare these results to the pre-mPCR time period and noted that because of the many factors associated with antimicrobial usage, they could not evaluate the mPCR ME panel for antimicrobial stewardship [37] . Mina et al. did find a significant difference in the duration antimicrobial usage, 9.5 ± 3.7 days in the mPCR group and 15.2 ± 5 days in the control group (p = 0.007). It is important to note the authors only conducted significance assessment on the presence of bacterial meningitis on the mPCR panel versus a control group that could have had non-bacterial meningitis, but did not have a mPCR panel collected [41] .

A recent prospective observational trial in France studied the effect of mPCR diagnosis of meningitis/encephalitis on the management of patients with suspected CNS infections. The use of an mPCR panel led to an earlier discontinuation of empiric antimicrobials in 32% of the cases. The authors additionally observed a reduction in the length of stay for 18% of patients. A significant limitation to this study is the absence of reporting tests of statistical significance [42•] . Overall, a lack of more generalizable data limits a more nuanced review of CNS mPCR use in antimicrobial stewardship.

Although there is limited evidence that the CNS mPCR panel reduces antimicrobial use, several groups reported potential cost savings that can be achieved by using mPCR in the diagnosis of CNS infections. DiDodato et al. estimated cost savings based on a standardized cost of stay in Canadian hospitals for CNS infections. Using observational data from preand-post introduction of the mPCR ME panel at a communitybased university affiliated hospital, they estimated a cost savings per patient case of $2319 CDN ($1693 USD), calculated by determining the change in time to discharge. The cost savings in their model were driven by time to definitive microbiologic reporting, which happened earlier in the group utilizing mPCR. Costs of microbiologic diagnosis during the same period were stable and thought to be offset by changes in the standard of care when utilizing mPCR, so the cost of the mPCR panel was not included in the final analysis [43] . In a separate study from France, the reduction in hospital stay from using an mPCR ME panel resulted in estimated savings of 201 €/patient (~$245 USD). Soucek et al. identified cost savings of $38.73 USD in antimicrobials when using a CNS mPCR panel. When including the cost of diagnostic testing, that gap narrowed to <$1 USD (P=0.15) [44] . These studies are useful in justifying the cost of the mPCR panel, which can run >$100 USD.

Additionally, several issues relating to the interpretation of CNS mPCR results have not been resolved. Several papers highlight concerns that the sensitivity of the BioFire CNS mPCR for Cryptococcus neoformans/gattii may be suboptimal when compared to traditional methods [37, [45] [46] [47] [48] . However, a recent systematic review of cases reported in the literature found that most reported cryptococcus results lacked an appropriate comparator method or were compared to only a serum cryptococcal antigen, concluding that there was a higher negative predictive value to the mPCR panel than individual studies suggested, with an overall sensitivity and specificity of >90% [39] . Finally, positive Human Herpes Virus 6 (HHV-6), Cytomegalovirus (CMV), and Herpes Simplex Virus (HSV) results must be interpreted in the appropriate context, as reactivation and active infection can both result as positive [39, 47] . At this time, mPCR CNS panels are promising for stewardship, but more study is needed to define best practices for their use.

The use of mPCR panels to guide antimicrobial therapy and enhance antimicrobial stewardship shows promise, but more studies are needed to define their most optimal use. Table 1 summarizes the key findings from our review of stewardship literature related to respiratory, GI and CNS mPCR panels. If mPCR panels are adopted, incorporation of these technologies in local treatment guidelines is critical. Guidelines help frontline clinicians best utilize these tests and help reinforce best antimicrobial management practices. These algorithms may or may not include procalcitonin, as recently, the diagnostic sensitivity and specificity of elevated procalcitonin for distinguishing viral from bacterial pneumonia has been called into question [49] .

Another way to optimize the use of mPCR is via EMRbased decision support. Moradi et al. did this via adding a Best Practice Alert into their EMR [25••] . EMR tools can activate based on pre-set data criteria and can provide guidance directly to providers. Adding a EMR stewardship visualization tool worked for a Veterans Affairs Health System Hospital and could be combined with any one of the mPCR panels to improve utilization of antibiotics [50] .

ASP personnel can actively review new mPCR results and provide best practice recommendations to providers directly. These efforts are most useful when ASP personnel are acting on these data in real-time [22, 23, 24••] . Compliance with ASP recommendations should be monitored and feedback to end users provided. When compliance is suboptimal, the reasons for this should be explored. ASP interventions utilizing realtime mPCR data are labor intensive and have significant implications for program staffing and resources.

In assessing the effectiveness of treatment guidelines incorporating mPCR panels, surveying providers about their rationale for following an algorithm (or not) may be useful to help optimize the use of these technologies. Importantly, providing feedback to providers about rates of antibiotic prescribing may improve subsequent antibiotic use [51] .

For GI and CNS mPCR panels, there are no published, peer-reviewed studies available at the time of this publication that explore the use of EMR-based decision support in the context of antimicrobial stewardship. Extrapolating from respiratory mPCR studies, EMR-based decision support may optimize the use of these technologies. For both GI and respiratory mPCR panels, diagnostic test stewardship (via test restriction) appears critically important [34, 52, 53] .

Respiratory, GI and CNS syndromic mPCR panels, as an isolated intervention, aid in the diagnosis of infectious pathogens yet do not consistently improve antimicrobial utilization. Wherever possible, these technologies should be incorporated into local treatment guidelines with active antimicrobial stewardship program oversight and support. The use of EMRbased decision support is also promising. Provider compliance with guidelines utilizing mPCR panels should be monitored and feedback should be provided. Additional research is needed to define best practices for the use of mPCR panels in both antimicrobial and diagnostic test stewardship.

Human and Animal Rights and Informed Consent All reported studies/ experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Syndromic panel-based testing in clinical microbiology

BioFire Receives FDA Clearance for FilmArray® Torch with FilmArray® Respiratory Panel and Submits Special 510(k) Applications for use with additional FilmArray® Panels

Direct-from-specimen pathogen identification: evolution of syndromic panels

Diagnosis and treatment of adults with communityacquired pneumonia. An Official Clinical Practice Guideline of the

Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea

Multiplex PCR for Detection and identification of microbial pathogens

Comparison of the Biofire FilmArray RP, Genmark eSensor RVP, Luminex xTAG RVPv1, and Luminex xTAG RVP Fast Multiplex Assays for Detection of Respiratory Viruses

Comparison of two multiplex methods for detection of respiratory viruses: FilmArray RP and xTAG RVP ▿

Clinical evaluation of the new high-throughput Luminex NxTAG Respiratory Pathogen Panel assay for multiplex respiratory pathogen detection

Implementation of FilmArray respiratory viral panel in a core laboratory improves testing turnaround time and patient care

Impact of early detection of respiratory viruses by multiplex PCR assay on clinical outcomes in adult patients

Clinical decision making in the emergency department setting using rapid PCR: results of the CLADE study group

Clinical utility of on-demand multiplex respiratory pathogen testing among adult outpatients

The clinical impact of the detection of potential etiologic pathogens of community-acquired pneumonia

Evaluation of a two-stage testing algorithm for the diagnosis of respiratory viral infections

Clinical impact of rapid molecular detection of respiratory pathogens in patients with acute respiratory infection

Multiplex PCR point of care testing versus routine, laboratorybased testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use

Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial

The rapid diagnosis of viral respiratory tract infections and its impact on antimicrobial stewardship programs

Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial

Provider decisions to treat respiratory illnesses with antibiotics: insights from a randomized controlled trial

Antimicrobial stewardship for hospitalized patients with viral respiratory tract infections

Rapid respiratory panel testing: impact of active antimicrobial stewardship

Implementation of a stewardship initiative on respiratory viral PCR-based antibiotic deescalation

Important as a directed stewardship intervention across a large hospital system looking at positive Respiratory mPCR and providing direct feedback to the ordering teams via trained antimicrobial stewardship provider

Recent quasi-experimental pre-and-post implementation study utilizing a best-practice alert to provide ordering clinicians with evidenced-based guidance on procalcitoninguided antimicrobial stewardship. Clinicians were alerted to the guidance when certain conditions were met in the electronic medical record

A Gastrointestinal PCR panel improves clinical management and lowers health care costs

Prospective multicenter study with large sample size compared to historic control that examined the impact of the BioFire GI panel on clinical resource utilization. Turnaround time and pathogen detection as percent of samples tested both improved with GI PCR. Fewer patients in the mPCR group had empiric antibiotics and there was a significant trend towards targeted over empiric therapy

The Perils of Multiplex Gastrointestinal pathogen panels: pseudooutbreaks of Salmonellae and Entamoeba histolytica in Immunocompromised Hosts

Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis

Performance of the Verigene® enteric pathogens test, Biofire FilmArray TM gastrointestinal panel and Luminex xTAG® gastrointestinal pathogen panel for detection of common enteric pathogens

Impact of gastrointestinal panel implementation on health care utilization and outcomes

Rapid molecular detection of gastrointestinal pathogens and its role in antimicrobial stewardship

Is follow-up testing with the FilmArray gastrointestinal multiplex PCR panel necessary?

Low yield of FilmArray GI panel in hospitalized patients with diarrhea: an opportunity for diagnostic stewardship intervention

A review of a 13-month period of FilmArray Meningitis/ Encephalitis panel implementation as a first-line diagnosis tool at a university hospital

A tertiary care center's experience with novel molecular meningitis/encephalitis diagnostics and implementation with antimicrobial stewardship

Clinical utilization of the FilmArray meningitis/encephalitis (ME) multiplex polymerase chain reaction (PCR) assay. Front Neurol

Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis

Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis

Contribution of the BioFire® FilmArray® meningitis/encephalitis panel: assessing antimicrobial duration and length of stay

Clinical benefits of FilmArray meningitis-encephalitis PCR assay in partially-treated bacterial meningitis in Israel

Impact of a multiplex PCR assay (FilmArray®) on the management of patients with suspected central nervous system infections

Cerebrospinal fluid analysis with the BioFire FilmArray meningitis/encephalitis molecular panel reduces length of hospital stay in patients with suspected central nervous system infections

Cost justification of the BioFire FilmArray meningitis/encephalitis panel versus standard of care for diagnosing meningitis in a community hospital

Culture-confirmed cryptococcal meningitis not detected by Cryptococcus PCR on the Biofire meningitis/encephalitis panel®

Evaluation of a commercial multiplex molecular panel for diagnosis of infectious meningitis and encephalitis

Multicenter evaluation of BioFire FilmArray meningitis/ encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens

False negative diagnostic errors with polymerase chain reaction for the detection of cryptococcal meningoencephalitis

Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis

Decreases in antimicrobial use associated with multihospital implementation of electronic antimicrobial stewardship tools

Behavioral interventions to reduce inappropriate antibiotic prescribing: a randomized pilot trial

Optimal timing of repeat multiplex molecular testing for respiratory viruses

Hardwiring diagnostic stewardship using electronic ordering restrictions for gastrointestinal pathogen testing

Publisher's NotePublisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Conflict of interest Theodore S. Rader, Michael P. Stevens, and Gonzalo Bearman declare that they have no conflict of interest.

Papers of particular interest, published recently, have been highlighted as: